Tuesday, May 17, 2011

Resolve Therapeutics Gains $2M

Seattle-based Resolve Therapeutics, a new startup developing treatments for lupus, said today that it has raised $2M in a initial close of a Series A funding round. The round came from New Science Ventures and Easton Capital. Resolve Therapeutics is headed by James Posada. As part of the funding, Peter Kiener, CEO of Zyngenia, has been named Chairman of its board; New Sciences Ventures' Somu Subramanian has joined the board as a member; and John Friedman, of Easton Capital, is now an observer. Resolve Therapeutics is developing RSLV-125, a novel targeted biologic therapy aimed at treating lupus. More information »